ABSTRACT

Introduction

Monoclonal antibodies (mAbs) have become an increasing source of biological treatments. Clinicians should make an effort to update their knowledge on mechanisms of action, indications, and adverse events of these novel therapies. Most of them have immunosuppressive effects and, therefore, vaccination is indicated.

Areas covered

vaccination of patients under mAbs therapies.

Expert opinion

Recommendations on vaccination are still based on expert recommendations and have not been updated in recent years. Specific recommendations for each mAb have not been addressed in the current literature. The aim of this comprehensive review was to collect all the therapeutic mAbs approved up to 1 January 2020 and, based on previous recommendations and the pharmaceutical characteristics of each drug, to propose an updated guide with recommendations on vaccination. Influenza, sequential pneumococcal and Hepatitis B vaccination in patients with negative serology were the only consistent recommendations. Hepatitis A vaccination was proposed for mAbs with special hepatotoxic characteristics. Other vaccines are reviewed and discussed. Several non-immunosuppressive mAbs were detected and, therefore, vaccinations not recommended. We hope that this review can serve as a starting point for compiling updated vaccination recommendations and collecting all the therapeutic mAbs approved up to 2020.

中文翻译：

---

接受单克隆抗体治疗的患者的疫苗接种：最新综合综述。

摘要

介绍

单克隆抗体（mAb）已成为越来越多的生物治疗方法。临床医生应努力更新他们对这些新颖疗法的作用机制，适应症和不良事件的认识。它们中的大多数具有免疫抑制作用，因此需要接种疫苗。

覆盖区域

在单克隆抗体疗法下对患者进行疫苗接种。

专家意见

关于疫苗接种的建议仍基于专家建议，并且近年来没有更新。当前文献中尚未解决针对每种mAb的具体建议。这项全面审查的目的是收集截至2020年1月1日批准的所有治疗性mAb，并根据以前的建议和每种药物的药物特性，提出包含疫苗接种建议的最新指南。唯一一致的建议是对血清学阴性的患者进行流感，连续肺炎球菌和乙肝疫苗接种。有人建议对具有特殊肝毒性特征的单克隆抗体进行甲型肝炎疫苗接种。审查和讨论了其他疫苗。检测到几种非免疫抑制性单克隆抗体，因此不建议接种疫苗。